Farallon co-chief investment officer Andrew Spokes
April 5, 2023 10:31 AM EDTUpdated 07:16 PM
People

Hedge fund slams Ex­elix­is for R&D man­age­ment, launch­es proxy fight for board seats (up­dat­ed)

Kyle LaHucik

Senior Reporter

A hedge fund is look­ing to re­fresh Ex­elix­is, propos­ing three board di­rec­tor nom­i­nees and launch­ing a proxy bat­tle that’s scru­ti­niz­ing the biotech’s R&D blue­print. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times